摘要
目的研究分析采用不同药物治疗危重症患者多重耐药菌感染的临床效果。方法选取2014年2月~2016年11月期间,在江西省九江市妇幼保健院接受治疗的多重耐药菌感染的危重症患者70例,随机分为观察组和对照组,各35例。对照组患者采用头孢哌酮钠舒巴坦钠治疗,观察组患者在此基础上加用美罗培南治疗,比较两组患者的治疗效果及不良反应情况。结果观察组患者的治疗有效率为91.4%,高于对照组患者的治疗有效率68.6%,差异具有统计学意义(P<0.05);观察组患者的细菌清除率高于对照组,细菌替换率及细菌感染率低于对照组,差异具有统计学意义(P<0.05);两组患者治疗前的WBC、ALT、ALB、Scr及CRP比较差异无统计学意义,两组患者治疗后的WBC、ALT、ALB、Scr及CRP与治疗前比较差异具有统计学意义(P<0.05);观察组患者的不良反应发生率为5.7%,低于对照组患者的不良反应发生率17.1%,差异具有统计学意义(P<0.05)。结论采用美罗培南治疗多重耐药菌感染的危重症患者的临床效果显著,且细菌清除率高,不良反应少。
Objective To study the clinical effects of different drugs in the treatment of multi-drug resistant infections in critically ill patients.Methods From February 2014 to November 2016, 70 critically ill patients with multi-drug resistant infections were treated in Jiujiang Maternal and Child Health Hospital of Jiangxi Province. They were randomly divided into observation group and control group,35cases in each goup. The patients
in the control group were treated with cefoperazone sodium and sulbactam sodium. The patients in the observation group were treated with meropenem.The therapeutic effects and adverse reactions of the two groups were compared. Results The effective rate of the observation group was 91.4%,which was 68.6% higher than that of the control group. The difference was statistically significant（P〈0.05）. The bacterial clearance rate of the observation group was higher than that of the control group, and the bacterial replacement rate was higher. The bacterial infection rate was lower than that of the control group, and the difference was statistically significant（P〈0.05）. There was no significant difference in WBC, ALT, ALB, Scr and CRP between the two groups before treatment. The WBC, ALT, ALB, Scr and CRP after treatment were significantly different from those before treatment and control group （P〈0.05）. The incidence of adverse reactions in the observation group was 5.7%, which was lower than that in the control group 17.1%, the difference was statistically significant（P〈0.05）. Conclusion The clinical effect of meropenem in the treatment of critically ill patients with multi-drug resistant infections is significant, with high bacterial clearance and few adverse reactions.
作者
梁小峰
Liang Xiaofeng(Department of pediatric Jiangxi Jiujiang Maternal and Child Health Care Hospital,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2018年第26期46-48,共3页
Contemporary Medicine
关键词
多重耐药菌感染
危重症
美罗培南
Multi-drug resistant infection
Critical illness
Meropenem
